Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.
News|Slideshows|April 13, 2023
Are Migraines Different in Women and Men?
Author(s)Steven A. King, MD, MS
Advertisement
Migraine headache (MHA) is a common neurologic disorder with prevalence greater among women than men in a 3:1 ratio. The difference is usually explained as being related to hormonal differences between the sexes. However, given that a significant number of men develop MHA, this explanation seems insufficient to fully explain the disproportionate ratio.
A new
Advertisement
Related to this article
The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
The FDA accepted Organon’s MIUDELLA supplemental application, but the proposed change, supporting data, and review timeline remain undisclosed.
A team-based blood pressure intervention delivered through primary care reduced dementia risk by 15% over 7 years.
Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.
Plasma p-tau217 levels helped estimate 5- and 10-year cognitive impairment risk in older adults without memory or thinking symptoms.
FDA cleared C2N’s PrecivityAD2 blood test to aid Alzheimer disease evaluation in symptomatic adults aged 40 years and older.
Advertisement
Advertisement
Trending on Patient Care Online
1
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
2
5 FDA Decisions for Primary Care to Know from September 2026
3
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
4
Fezolinetant Linked to 2.6 Fewer Nighttime Awakenings in Women With Menopausal VMS
5